PDF DatasheetHuman Anti-Progesterone Receptor Antibody Product Attributes
Progesterone Receptor Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in Progesterone Receptor antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in glandular cells in the cervix, uterine and endometrium, cells in the endometrial stroma in endometrium, glandular cells in the fallopian tube and smooth muscle cells in the smooth muscle. More moderate antibody staining intensity was present in glandular cells in the cervix, uterine and endometrium, cells in the endometrial stroma in endometrium, glandular cells in the fallopian tube and smooth muscle cells in the smooth muscle. Low, but measureable presence of Progesterone Receptor could be seen in. We were unable to detect Progesterone Receptor in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Progesterone Receptor expression as measured by anti-Progesterone Receptor antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | ++ | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| PGR Variability | ++ | ++ | + | + | +++ | + | ++ | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Progesterone Receptor General Information | |
|---|---|
| Alternate Names | |
| Progesterone Receptor, Anti-Progesterone Receptor antibody, anti-PGR antibody, PGR | |
| Molecular Weight | |
| PR-A (81kDa), PR-B (116kDa). | |
| Chromosomal Location | |
| 11q22.1 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | PGR |
| Entrez Gene ID | 5241 |
| Ensemble Gene ID | ENSG00000082175 |
| RefSeq Protein Accession(s) | NP_001258091, XP_006718921, NP_001258090, XP_011541171, NP_000917, NP_001189403 |
| RefSeq mRNA Accession(s) | XM_006718858, XM_011542869, NM_001202474, NR_073143 NM_001271162, NR_073141, NR_073142, NM_001271161, NM_000926 |
| RefSeq Genomic Accession(s) | NG_016475, NC_018922, NC_000011 |
| UniProt ID(s) | P06401 |
| UniGene ID(s) | P06401 |
| HGNC ID(s) | 8910 |
| Cosmic ID(s) | PGR |
| KEGG Gene ID(s) | hsa:5241 |
| PharmGKB ID(s) | PA266 |
| General Description of Progesterone Receptor. | |
| This MAb is specific to progesterone receptor, shows minimal cross-reaction with other members of the family. Progesterone receptor is expressed as two major isoforms, PR-A (81kDa), PR-B (116kDa). Expression of PgR has been suggested to reflect a intact estrogen regulatory machinery, therefore, predict better clinical response to endocrine therapy than ER alone. | |
There are no reviews yet.